Skip to main content
SpringerLink
Log in

Rituximab good value for money in follicular lymphoma

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chen Q, et al. Comparing The Cost-Effectiveness Of Rituximab Maintenance (MR) and Radioimmunotherapy (RIT) Consolidation Therapy Following First-Line Chemo/Immunochemotherapies For Follicular Lymphoma. 55th Annual Meeting and Exposition of the American Society of Hematology : abstr. 2923, 8 Dec 2013.

  2. Prica A, et al. Frontline Rituximab Monotherapy Induction Versus a Watch and Wait Approach For Asymptomatic Advanced Stage Follicular Lymphoma: A Cost-Effectiveness Analysis. 55th Annual Meeting and Exposition of the American Society of Hematology : abstr. 2941, 8 Dec 2013.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rituximab good value for money in follicular lymphoma. PharmacoEcon Outcomes News 695, 8 (2014). https://doi.org/10.1007/s40274-014-1009-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1009-6

Search

Navigation